Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico

253 Gheita TA, El-Gazzar II, Azkalany G, El-Fishawy HS, El-Faramawy A. High-sensitivity
C-reactive protein (hs-CRP) in systemic lupus erythematosus patients without cardiac
involvement; relation to disease activity, damage and intima-media thickness. Egypt
Rheumatol 2012; 34: 147–152.
254 Barnes E V, Narain S, Naranjo A, Shuster J, Segal MS, Sobel ES et al. High sensitivity C-
reactive protein in systemic lupus erythematosus : relation to disease activity , clinical
presentation and implications for cardiovascular risk. Lupus 2005; 14: 576–582.
255 Lee SS, Singh S, Link K, Petri M. High-sensitivity C-reactive protein as an associate of
clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis
Rheum 2008; 38: 41–54.
256 Lee S, Singh S, Magder LS, Petri M. Predictors of high sensitivity C-reactive protein levels
in patients with systemic lupus erythematosus. Lupus 2008; : 114–123.
257 Bertoli A, Vilá L, Reveille J, Alarcón G. Systemic lupus erythaematosus in a multiethnic
US cohort (LUMINA) LIII: disease expression and outcome in acute onset lupus. Ann
Rheum Dis 2008; 67: 500–504.
258 Banerjee S, Sarkar RN, Mullick OS, Bhattacharyya K, Das A, Bhattacharya R et al. A
cross-sectional study to assess the association of systemic lupus erythematsous disease
activity with levels of high sensitivity C-reactive protein. Indian J Rheumatol 2013; 8: 61–
64.
259 Mok C, Birmingham D. High-sensitivity C-reactive protein, disease activity, and
cardiovascular risk factors in systemic lupus erythematosus. Arthritis Care Res 2013; 65:
441–447.
260 Pradhan V, Rajadhyaksha A, Patwardhan M, Surve P, Dhavale N, Pandit P et al. High
sensitivity C-reactive protein (hsCRP): Association with clinical subsets in systemic lupus
erythematosus (SLE) patients from Western India. Indian J Rheumatol 2013; 8: 65–67.
261 Sjöwall C, Bengtsson A a, Sturfelt G, Skogh T. Serum levels of autoantibodies against
monomeric C-reactive protein are correlated with disease activity in systemic lupus
erythematosus. Arthritis Res Ther 2004; 6: R87–R94.
262 Valentijn R, van Overeem H, Hazevoet H, Hermans J, Cats A, Daha M et al. The value of
complement and immune complex determinations in monitoring disease activity in
patients with systemic lupus erythematosus. Arthritis Rheum 1985; 28: 904–913.
263 Ng KP, Manson JJ, Rahman A, Isenberg D a. Association of antinucleosome antibodies
with disease flare in serologically active clinically quiescent patients with systemic lupus
erythematosus. Arthritis Rheum 2006; 55: 900–904.
264 Rekvig OP, van der Vlag J, Seredkina N. Review: antinucleosome antibodies: a critical
reflection on their specificities and diagnostic impact. Arthritis Rheumatol 2014; 66: 1061–
1069.
265 Thudi A, Yin SU, Wandstrat AMYE, Li Q, Olsen NJ. Vitamin D Levels and Disease
Status in Texas Patients With Systemic Lupus Erythematosus. Am J Med Sci 2008; 355:
99–104.
454 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS